fluorouracil has been researched along with Soft Tissue Neoplasms in 28 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Soft Tissue Neoplasms: Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
| Excerpt | Relevance | Reference |
|---|---|---|
| "PURPOSE To evaluate trastuzumab (H) and docetaxel (T) with or without capecitabine (X) as first-line combination therapy for human epidermal growth factor receptor 2 (HER2) -positive advanced breast cancer." | 9.14 | Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. ( Barton, C; Button, P; de Fátima Dias Gaui, M; Hersberger, V; Jassem, J; Morales-Vasquez, F; Pivot, X; Reyes, DO; Torres, AA; Wardley, AM; Zetina, LM, 2010) |
| "This study was conducted to determine, in patients with advanced-stage breast cancer, the maximum tolerated dose (MTD) of capecitabine administered orally for 7 days followed by a 7-day rest (7/7), a schedule based on a mathematical method for the optimization of anticancer drug scheduling." | 9.13 | Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. ( Dugan, U; Edwards, C; Feigin, K; Hudis, C; Norton, L; Patil, S; Tan, KL; Theodoulou, M; Traina, TA, 2008) |
| "To assess the activity of paclitaxel in combination with 5-fluorouracil (5-FU) and leucovorin in breast cancer, a phase II trial was conducted in women with metastatic disease." | 9.09 | Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer. ( Cohen, A; Hande, KR; Johnson, DH; Meshad, M; Nicholson, BP; Paul, DM; Shyr, Y, 2000) |
| "Because leucovorin increases the antitumor activity of 5-fluorouracil (5-FU) in multiple tumor model systems, we performed a clinical trial to evaluate this combination in women who had received one or no prior chemotherapy regimens for metastatic breast cancer." | 9.07 | 5-Fluorouracil plus leucovorin in women with metastatic breast cancer. A phase II study. ( Allegra, CJ; Buckner, JC; Edmonson, JH; Ingle, JN; Loprinzi, CL; Schaid, DJ, 1991) |
| " 5-Fluorouracil, and prednisone (CFP) in patients with advanced breast cancer." | 9.07 | A randomized trial of cyclophosphamide, doxorubicin, and prednisone versus cyclophosphamide, 5-fluorouracil, and prednisone in patients with metastatic breast cancer. ( Ahmann, DL; Bisel, HF; Buckner, JC; Ingle, JN; Long, HJ; Rubin, J; Schaid, DJ; Schutt, AJ, 1991) |
| "Celecoxib was never discontinued for toxicity." | 6.73 | Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. ( Carlini, P; Cognetti, F; Fabi, A; Ferretti, G; Gelibter, A; Melucci, E; Metro, G; Milella, M; Mottolese, M; Papaldo, P; Russillo, M; Sperduti, I; Tomao, S, 2008) |
| "Capecitabine is an orally administered precursor of 5'-deoxy-5-fluorouridine that was rationally designed to generate 5-fluorouracil (5-FU) preferentially in tumor tissue." | 6.73 | Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer. ( Alessandroni, P; Baldelli, AM; Casadei, V; Catalano, G; Catalano, V; Ceccolini, M; Fedeli, A; Fedeli, SL; Giordani, P; Rossi, D, 2007) |
| "Metastatic breast cancer remains an incurable disease and the median overall survival has not significantly improved over the past two decades." | 6.69 | Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? A phase II randomized trial of vinorelbine versus 5-fluorouracil plus leucovorin versus combination of mitoxantrone, 5-fluorouracil plus leucovorin. ( Comandini, D; Fusco, V; Merlini, L; Naso, C; Palumbo, R; Porcile, G; Pronzato, P; Repetto, L; Rosso, R; Simoni, C; Venturino, A, 2000) |
| "PURPOSE To evaluate trastuzumab (H) and docetaxel (T) with or without capecitabine (X) as first-line combination therapy for human epidermal growth factor receptor 2 (HER2) -positive advanced breast cancer." | 5.14 | Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. ( Barton, C; Button, P; de Fátima Dias Gaui, M; Hersberger, V; Jassem, J; Morales-Vasquez, F; Pivot, X; Reyes, DO; Torres, AA; Wardley, AM; Zetina, LM, 2010) |
| "This study was conducted to determine, in patients with advanced-stage breast cancer, the maximum tolerated dose (MTD) of capecitabine administered orally for 7 days followed by a 7-day rest (7/7), a schedule based on a mathematical method for the optimization of anticancer drug scheduling." | 5.13 | Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. ( Dugan, U; Edwards, C; Feigin, K; Hudis, C; Norton, L; Patil, S; Tan, KL; Theodoulou, M; Traina, TA, 2008) |
| "To assess the activity of paclitaxel in combination with 5-fluorouracil (5-FU) and leucovorin in breast cancer, a phase II trial was conducted in women with metastatic disease." | 5.09 | Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer. ( Cohen, A; Hande, KR; Johnson, DH; Meshad, M; Nicholson, BP; Paul, DM; Shyr, Y, 2000) |
| "The relationship between the response to chemotherapy with cyclophosphamide, epirubicin and fluorouracil as well as the time to progression of metastasised breast cancer and DNA ploidy and S-phase fraction (SPF) of primary tumours was examined using paraffin-embedded tumour tissue from 81 patients." | 5.08 | Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer? ( Blomqvist, C; Franssila, K; Hietanen, P; Niskanen, E; Nordling, S; Wasenius, VM, 1995) |
| "Because leucovorin increases the antitumor activity of 5-fluorouracil (5-FU) in multiple tumor model systems, we performed a clinical trial to evaluate this combination in women who had received one or no prior chemotherapy regimens for metastatic breast cancer." | 5.07 | 5-Fluorouracil plus leucovorin in women with metastatic breast cancer. A phase II study. ( Allegra, CJ; Buckner, JC; Edmonson, JH; Ingle, JN; Loprinzi, CL; Schaid, DJ, 1991) |
| " 5-Fluorouracil, and prednisone (CFP) in patients with advanced breast cancer." | 5.07 | A randomized trial of cyclophosphamide, doxorubicin, and prednisone versus cyclophosphamide, 5-fluorouracil, and prednisone in patients with metastatic breast cancer. ( Ahmann, DL; Bisel, HF; Buckner, JC; Ingle, JN; Long, HJ; Rubin, J; Schaid, DJ; Schutt, AJ, 1991) |
| "Celecoxib was never discontinued for toxicity." | 2.73 | Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. ( Carlini, P; Cognetti, F; Fabi, A; Ferretti, G; Gelibter, A; Melucci, E; Metro, G; Milella, M; Mottolese, M; Papaldo, P; Russillo, M; Sperduti, I; Tomao, S, 2008) |
| "Capecitabine is an orally administered precursor of 5'-deoxy-5-fluorouridine that was rationally designed to generate 5-fluorouracil (5-FU) preferentially in tumor tissue." | 2.73 | Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer. ( Alessandroni, P; Baldelli, AM; Casadei, V; Catalano, G; Catalano, V; Ceccolini, M; Fedeli, A; Fedeli, SL; Giordani, P; Rossi, D, 2007) |
| "Metastatic breast cancer remains an incurable disease and the median overall survival has not significantly improved over the past two decades." | 2.69 | Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? A phase II randomized trial of vinorelbine versus 5-fluorouracil plus leucovorin versus combination of mitoxantrone, 5-fluorouracil plus leucovorin. ( Comandini, D; Fusco, V; Merlini, L; Naso, C; Palumbo, R; Porcile, G; Pronzato, P; Repetto, L; Rosso, R; Simoni, C; Venturino, A, 2000) |
| "Fifty patients with advanced breast cancer were treated by high dose cisplatin (DDP) combination chemotherapy during the period of August 1984 to June 1991." | 2.67 | [High dose cisplatin combination chemotherapy for advanced breast cancer--a report on 50 cases]. ( Zhou, JC, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (32.14) | 18.7374 |
| 1990's | 7 (25.00) | 18.2507 |
| 2000's | 10 (35.71) | 29.6817 |
| 2010's | 2 (7.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, X | 1 |
| Sanderson, SM | 1 |
| Dai, Z | 1 |
| Reid, MA | 1 |
| Cooper, DE | 1 |
| Lu, M | 1 |
| Richie, JP | 1 |
| Ciccarella, A | 1 |
| Calcagnotto, A | 1 |
| Mikhael, PG | 1 |
| Mentch, SJ | 1 |
| Liu, J | 1 |
| Ables, G | 1 |
| Kirsch, DG | 1 |
| Hsu, DS | 1 |
| Nichenametla, SN | 1 |
| Locasale, JW | 1 |
| Waters, SH | 1 |
| Gillibrand, A | 1 |
| Berry, H | 1 |
| Kumar, S | 1 |
| Velikova, G | 1 |
| Dodwell, DJ | 1 |
| Perren, TJ | 1 |
| Wardley, AM | 1 |
| Pivot, X | 1 |
| Morales-Vasquez, F | 1 |
| Zetina, LM | 1 |
| de Fátima Dias Gaui, M | 1 |
| Reyes, DO | 1 |
| Jassem, J | 1 |
| Barton, C | 1 |
| Button, P | 1 |
| Hersberger, V | 1 |
| Torres, AA | 1 |
| Birtle, AJ | 2 |
| Newby, JC | 1 |
| Harland, SJ | 1 |
| Tytherleigh, MG | 1 |
| Cohen, CE | 1 |
| Glynne-Jones, R | 1 |
| Livingstone, J | 1 |
| Gilbert, J | 1 |
| Yap, YS | 1 |
| Kendall, A | 1 |
| Walsh, G | 1 |
| Banerji, U | 1 |
| Johnston, SR | 1 |
| Smith, IE | 1 |
| O'Brien, M | 1 |
| Wada, Y | 1 |
| Hirayama, Y | 1 |
| Seki, R | 1 |
| Konuma, Y | 1 |
| Kohda, K | 1 |
| Yoshida, M | 1 |
| Nakamura, Y | 1 |
| Obata, M | 1 |
| Ando, M | 1 |
| Fabi, A | 1 |
| Metro, G | 1 |
| Papaldo, P | 1 |
| Mottolese, M | 1 |
| Melucci, E | 1 |
| Carlini, P | 1 |
| Sperduti, I | 1 |
| Russillo, M | 1 |
| Gelibter, A | 1 |
| Ferretti, G | 1 |
| Tomao, S | 1 |
| Milella, M | 1 |
| Cognetti, F | 1 |
| Rossi, D | 1 |
| Alessandroni, P | 1 |
| Catalano, V | 1 |
| Giordani, P | 1 |
| Fedeli, SL | 1 |
| Fedeli, A | 1 |
| Baldelli, AM | 1 |
| Casadei, V | 1 |
| Ceccolini, M | 1 |
| Catalano, G | 1 |
| Traina, TA | 1 |
| Theodoulou, M | 1 |
| Feigin, K | 1 |
| Patil, S | 1 |
| Tan, KL | 1 |
| Edwards, C | 1 |
| Dugan, U | 1 |
| Norton, L | 1 |
| Hudis, C | 1 |
| Takeuchi, S | 2 |
| Akahoshi, Y | 1 |
| Kasai, C | 2 |
| Nishimoto, Y | 1 |
| Citrin, DL | 1 |
| Elson, P | 1 |
| DeWys, WD | 1 |
| Pinnamaneni, K | 1 |
| Yap, HY | 1 |
| Buzdar, AU | 2 |
| Distefano, A | 1 |
| Blumenschein, GR | 2 |
| Valagussa, P | 1 |
| Tess, JD | 1 |
| Rossi, A | 1 |
| Tancini, G | 1 |
| Banfi, A | 1 |
| Bonadonna, G | 1 |
| Jardines, L | 1 |
| Callans, LS | 1 |
| Torosian, MH | 1 |
| Hietanen, P | 1 |
| Blomqvist, C | 1 |
| Wasenius, VM | 1 |
| Niskanen, E | 1 |
| Franssila, K | 1 |
| Nordling, S | 1 |
| Zhou, JC | 1 |
| Venturino, A | 1 |
| Comandini, D | 1 |
| Simoni, C | 1 |
| Merlini, L | 1 |
| Naso, C | 1 |
| Palumbo, R | 1 |
| Fusco, V | 1 |
| Porcile, G | 1 |
| Pronzato, P | 1 |
| Rosso, R | 1 |
| Repetto, L | 1 |
| Nicholson, BP | 1 |
| Paul, DM | 1 |
| Hande, KR | 1 |
| Shyr, Y | 1 |
| Meshad, M | 1 |
| Cohen, A | 1 |
| Johnson, DH | 1 |
| Pinedo, HM | 1 |
| Kenis, Y | 1 |
| Vaage, J | 1 |
| Costanza, ME | 1 |
| Legha, SS | 1 |
| Smith, TL | 1 |
| Hortobagyi, GN | 1 |
| Swenerton, KD | 1 |
| Gehan, EA | 1 |
| Bodey, GP | 1 |
| Freireich, EJ | 1 |
| Sato, M | 1 |
| Kushida, Y | 1 |
| Matsunaga, T | 1 |
| Loprinzi, CL | 1 |
| Ingle, JN | 2 |
| Schaid, DJ | 2 |
| Buckner, JC | 2 |
| Edmonson, JH | 1 |
| Allegra, CJ | 1 |
| Ahmann, DL | 1 |
| Bisel, HF | 1 |
| Schutt, AJ | 1 |
| Long, HJ | 1 |
| Rubin, J | 1 |
| Porile, JL | 1 |
| Olopade, OI | 1 |
| Hoffman, PC | 1 |
| Bolla, M | 1 |
| Borgel, J | 1 |
| Winckel, P | 1 |
| Vrousos, C | 1 |
| Swiercz, P | 1 |
| Kreuter, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Single-blind, Multicenter, Parallel Group Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) in Combination With Docetaxel on Recurrent or Metastatic Breast Cancer Patients With Positive HER2[NCT05301010] | Phase 3 | 128 participants (Actual) | Interventional | 2018-02-02 | Completed | ||
| Randomized, Single-blind, Multicenter, Parallel Group Clinical Trial to Assess Pharmacokinetic Parameters, Safety of NNG-TMAB (Trastuzumab) in Combination With Docetaxel on Recurrent or Metastatic Breast Cancer Patients With Positive HER2.[NCT05301530] | Phase 1 | 50 participants (Actual) | Interventional | 2019-05-27 | Completed | ||
| A Prospective, Randomized, Open, Multi-center Phase III Clinical Study Comparing Efficacy and Safety of Sequential T-FEC and TX-XEC as Post-operative Adjuvant Chemotherapy Options for the Treatment of Triple-negative Breast Cancer[NCT01642771] | Phase 3 | 636 participants (Anticipated) | Interventional | 2012-06-30 | Active, not recruiting | ||
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for fluorouracil and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Recurrent breast cancer: presentation, diagnosis, and treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; Breast | 1993 |
Chemotherapy of advanced soft-tissue sarcomas in adults.
Topics: Adult; Antineoplastic Agents; Bone Marrow; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; | 1977 |
12 trials available for fluorouracil and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Brain Neoplasms; Br | 2008 |
Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplas | 2007 |
Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; | 2008 |
Treatment of metastatic prostate cancer. An analysis of response criteria in patients with measurable soft tissue disease.
Topics: Acid Phosphatase; Aged; Bone Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Evaluation; Fluo | 1984 |
Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclo | 1995 |
[High dose cisplatin combination chemotherapy for advanced breast cancer--a report on 50 cases].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cisplatin; | 1993 |
Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? A phase II randomized trial of vinorelbine versus 5-fluorouracil plus leucovorin versus combination of mitoxantrone, 5-fluorouracil plus leucovorin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Femal | 2000 |
Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2000 |
Chemotherapy of advanced soft-tissue sarcomas in adults.
Topics: Adult; Antineoplastic Agents; Bone Marrow; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; | 1977 |
5-Fluorouracil plus leucovorin in women with metastatic breast cancer. A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Fema | 1991 |
A randomized trial of cyclophosphamide, doxorubicin, and prednisone versus cyclophosphamide, 5-fluorouracil, and prednisone in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1991 |
15 other studies available for fluorouracil and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Dietary methionine influences therapy in mouse cancer models and alters human metabolism.
Topics: Animals; Cell Line, Tumor; Colorectal Neoplasms; Diet; Disease Models, Animal; Female; Fluorouracil; | 2019 |
Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone | 2009 |
Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; E | 2004 |
Combined surgery and chemoradiation as a treatment for the Buschke-Löwenstein tumour.
Topics: Abdominal Neoplasms; Adult; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinom | 2006 |
Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer--how low can you go?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxyc | 2007 |
[Long- term remission survival with a case of rectal carcinoid tumor with metastasis in the soft tissue effectively treated with the combination therapy of irinotecan/5-fluorouracil/levofolinate followed by resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoid Tumor; Chemotherapy, Adjuvan | 2007 |
[Clinical evaluation on the sensitivity test for anti-cancer agents in malignant bone and soft-tissue tumors].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; | 1984 |
Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neopla | 1984 |
Adjuvant CMF effect on site of first recurrence, and appropriate follow-up intervals, in operable breast cancer with positive axillary nodes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 1981 |
Effects of combination drug therapy on the subcutaneous and pulmonary growth of a slow and a fast-growing C3H/He mammary carcinoma.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Doxorubicin; Drug Resistance; Drug Therapy, Combin | 1979 |
Complete remissions in metastatic breast cancer treated with combination drug therapy.
Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Castration; Cycloph | 1979 |
[Clinical studies on preoperative continuous intra-arterial chemotherapy in the treatment of malignant soft tissue tumors].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheterization; Cisplatin; | 1991 |
Gastric adenocarcinoma presenting with soft tissue masses.
Topics: Adenocarcinoma; Aged; Fluorouracil; Humans; Male; Soft Tissue Neoplasms; Stomach Neoplasms; Thigh | 1990 |
[Combination cisplatin, fluorouracil and low-dose radiotherapy in recurrent soft tissue sarcomas].
Topics: Cisplatin; Combined Modality Therapy; Fluorouracil; Humans; Neoplasm Recurrence, Local; Sarcoma; Sof | 1986 |
Poly(alkyl acrylate) nanoparticles.
Topics: Acrylic Resins; Animals; Antibody Formation; Antigens; Chemical Phenomena; Chemistry; Colloids; Dact | 1985 |